Vaccinex, Inc.

NASDAQ:VCNX

1.31 (USD) • At close December 23, 2024
Bedrijfsnaam Vaccinex, Inc.
Symbool VCNX
Munteenheid USD
Prijs 1.31
Beurswaarde 3,506,398
Dividendpercentage 0%
52-weken bereik 0.76 - 13.02
Industrie Biotechnology
Sector Healthcare
CEO Dr. Maurice Zauderer Ph.D.
Website https://www.vaccinex.com

An error occurred while fetching data.

Over Vaccinex, Inc.

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody

Vergelijkbare Aandelen

Daxor Corporation logo

Daxor Corporation

DXR

8.3 USD

Reneo Pharmaceuticals, Inc. logo

Reneo Pharmaceuticals, Inc.

RPHM

18.2 USD

Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

ALGS

38.85 USD

Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc.

LRMR

3.96 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.452 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)